Ipsen in the news

Ipsen accelerates drug discovery through advanced screening tools and strategic partnerships, evidenced by its rapid progression of the IPN60300 antibody drug conjugate into Phase I/II trials.

Ipsen's stock dipped below –140.50 support then recovered, despite recent declines and increased selling pressure from a generic drug approval, while the company raised H1 2026 targets.

Ipsen's stock recovered above its support level of —140.50 despite recent declines due to generic competition for Somatuline and an analyst downgrade.

Ipsen reported robust H1 2026 financial results with 23.5% sales growth, upgraded its full-year guidance, and advanced its pipeline with positive Phase III readouts for Dysport and Iqirvo, alongside strategic late-stage acquisitions.

Ipsen emphasizes health literacy to ensure patients understand complex scientific advancements in healthcare, focusing on clear communication and patient involvement to remove barriers between progress and those it serves.

Following Henri Beaufour's death, his Ipsen shares were transferred to the Alasol Foundation, maintaining the family's significant control over the pharmaceutical group, which specializes in oncology, rare diseases, and neuroscience.

Ipsen is participating in the Deutsche Bank Depositary Receipts Virtual Investor Conference, with Craig Marks, VP of Investor Relations, presenting.

The net current asset value per share for Ipsen SA (HAN:I7G) is presented.

Ipsen SA exceeded semiannual earnings and revenue estimates, with analysts expecting continued growth in the next period.

Ipsen is implementing My Green Lab Certification at its Dublin and Wrexham sites to embed sustainability into laboratory operations and reduce environmental impact.

Ipsen conducted a share buy-back program on September 21 and 22, 2026, repurchasing a total of 46,805 shares across multiple markets.

Analysts from Alphavalue and Barclays adjusted their recommendations for Crédit Agricole SA, Bureau Veritas, and Ipsen on September 28, 2026.

Ipsen repurchased 46,805 of its own shares across various markets on September 21 and 22, 2026, at a weighted average price of 147.0812.

Ipsen bought back 46,805 shares at an average price of €147 per share on September 21 and 22, 2026.

Ipsen's stock dropped following FDA approval of Amneal's generic Somatuline, impacting sales forecasts despite previous generic manufacturing issues.

The document details various rating methodologies for Ipsen shares on Euronext Paris, including Trader, Investor, Global, Quality, and ESG MSCI scores.

Ipsen's stock price dropped by 3.89% in Paris, closing at 143.300€, with a significant 8.08% decline over the past seven days, despite a 28.41% annual increase.

Ipsen's governance changes and short-term stock dip come amid a positive long-term outlook, with the company potentially undervalued by 11% due to future pipeline catalysts, though risks related to product reliance and trial execution remain.